Breaking immunological tolerance to melanocyte differentiation antigens by hypopigmenting agents: a new means for melanoma immunotherapy?

Abstract	The hypopigmenting agent monobenzone induces inflammatory responses only in pigmented skin as well as depigmentation in areas not directly exposed to the drug. Both observations have been ascribed to the possible induction of adaptive immune responses against melanocytes. In this issue, van den Boorn et al. provide direct evidence confirming this hypothesis. Since the monobenzone-induced immune responses target melanocyte-differentiation antigens, this report opens the opportunity for a simple and instantaneous deployable immunotherapy of melanoma.
Authors	Jürgen C Becker, David Schrama
Journal	The Journal of investigative dermatology (J Invest Dermatol) Vol. 131 Issue 6 Pg. 1185-7 (Jun 2011) ISSN: 1523-1747 [Electronic] United States
PMID	21566576 (Publication Type: Comment, Journal Article)
Chemical References	Hydroquinones monobenzone
Topics	Adaptive Immunity (drug effects) Cell Differentiation Humans Hydroquinones (pharmacology, therapeutic use) Immune Tolerance (drug effects) Immunotherapy Melanocytes (cytology, drug effects, immunology) Melanoma (therapy) Skin Pigmentation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!